SHANGHAI, China, Aug. 25, 2005--Lnoppen, based in Shanghai has invited Europe's GalbraithWight to deliver strategy training in China, to Pharmaceutical company leaders.
Colin Wight, CEO and owner of GalbraithWight commented that, "China is currently number nine in the world Pharma rankings, but has substantial aspirations for growth. The market is expected to reach the number five spot by 2010 and the Chinese Government is supporting Industry reconstruction. Currently, relatively few people in China have access to Western standards of medical care, but that will change as their economic surge continues. In this respect, China may be seen as an 'emerging Pharmaceutical market, and it's already ranked number 9."
When asked whether his Chinese audience were looking for training to help them at home or to better manage their subsidiaries abroad, Mr Wight replied, "Apparently both. They chose us because of the depth of our international strategy work, particularly across Europe. They also like the fact that we focus 100% on Pharmaceutical marketing."
The training will focus on developing and extending product and franchise revenues throughout the Product Life Cycle. GalbraithWight will deliver this training in Shanghai.
GalbraithWight provide business consultancy, Marketing Excellence training and the Environmental Healthcare Business Intelligence Service, HiSBIS. For more information, please contact Mark Boyden, Vice President - Marketing & Business Development at 0772.309.8657 or m.boyden@galbraithwight.com
